Literature DB >> 19533054

[Methicillin-resistant Staphylococcus aureus (MRSA) infections. Epidemiology, diagnostics, therapy, and prevention].

Peter Heeg1, Klaus Schröppel.   

Abstract

The increasing number of complicated soft-tissue or invasive infections caused by methicillin-resistant Staphylococcus aureus (MRSA) is a frequent reason for elaborate treatment regimens. Unidentified MRSA carriers may be the origin of endemic spread to other patients and medical staff. Recently, community-associated cMRSA with particular virulence factors were isolated from persons without the typical history of hospital contacts. Molecular tools for the timely detection of the mecA resistance gene for the identification of MRSA in medical test specimens have become a standard approach in MRSA-related diagnostic procedures. The actual therapy of MRSA infections requires consideration of both the appropriate spectrum of activity and the adequate pharmacological properties of a chosen antimicrobial. Preventive strategies rely on the consistent application of standard hygiene precautions, which have to be supplemented with increased barriers for the isolation of identified MRSA patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19533054     DOI: 10.1007/s00063-009-1096-5

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


  18 in total

1.  Risk factors for persistent carriage of methicillin-resistant Staphylococcus aureus.

Authors:  S Harbarth; N Liassine; S Dharan; P Herrault; R Auckenthaler; D Pittet
Journal:  Clin Infect Dis       Date:  2000-11-10       Impact factor: 9.079

Review 2.  Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks.

Authors:  J Kluytmans; A van Belkum; H Verbrugh
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

Review 3.  Control of endemic MRSA-what is the evidence? A personal view.

Authors:  C Marshall; S Wesselingh; M McDonald; D Spelman
Journal:  J Hosp Infect       Date:  2004-04       Impact factor: 3.926

Review 4.  How often do asymptomatic healthcare workers cause methicillin-resistant Staphylococcus aureus outbreaks? A systematic evaluation.

Authors:  Ralf-Peter Vonberg; Sabine Stamm-Balderjahn; Sonja Hansen; Irina Zuschneid; Henning Ruden; Michael Behnke; Petra Gastmeier
Journal:  Infect Control Hosp Epidemiol       Date:  2006-09-21       Impact factor: 3.254

5.  Linezolid eradicates MRSA better than vancomycin from surgical-site infections.

Authors:  John Weigelt; Haytham M A Kaafarani; Kamal M F Itani; Robert N Swanson
Journal:  Am J Surg       Date:  2004-12       Impact factor: 2.565

6.  Identification of methicillin-resistant Staphylococcus aureus (MRSA): Comparison of a new molecular genetic test kit (GenoType MRSA) with standard diagnostic methods.

Authors:  K M Otte; S Jenner; H V Wulffen
Journal:  Clin Lab       Date:  2005       Impact factor: 1.138

7.  Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections.

Authors:  John Weigelt; Kamal Itani; Dennis Stevens; William Lau; Matthew Dryden; Charles Knirsch
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

8.  New real-time PCR assay for rapid detection of methicillin-resistant Staphylococcus aureus directly from specimens containing a mixture of staphylococci.

Authors:  A Huletsky; R Giroux; V Rossbach; M Gagnon; M Vaillancourt; M Bernier; F Gagnon; K Truchon; M Bastien; F J Picard; A van Belkum; M Ouellette; P H Roy; M G Bergeron
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

9.  Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia.

Authors:  Richard G Wunderink; Jordi Rello; Sue K Cammarata; Rodney V Croos-Dabrera; Marin H Kollef
Journal:  Chest       Date:  2003-11       Impact factor: 9.410

10.  Emergence of methicillin-resistant Staphylococcus aureus of animal origin in humans.

Authors:  Inge van Loo; Xander Huijsdens; Edine Tiemersma; Albert de Neeling; Nienke van de Sande-Bruinsma; Desiree Beaujean; Andreas Voss; Jan Kluytmans
Journal:  Emerg Infect Dis       Date:  2007-12       Impact factor: 6.883

View more
  1 in total

1.  [Epidemiology of and preventive measures for multiresistant pathogens].

Authors:  E-B Kruse; M Dettenkofer
Journal:  Ophthalmologe       Date:  2010-04       Impact factor: 1.059

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.